Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.
about
Nucleoside/nucleotide analogues in the treatment of chronic hepatitis BIn vivo assessment of mitochondrial toxicity of metacavir in Rhesus monkeys after three months of intravenous administration.DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.Lamivudine/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion.Evaluation of mitochondrial toxicity in Marmota himalayana treated with metacavir, a novel 2',3'-dideoxyguanosine prodrug for treatment of hepatitis B Virus.Safety and efficacy of entecavir for the treatment of chronic hepatitis B.Presteady state kinetic investigation of the incorporation of anti-hepatitis B nucleotide analogues catalyzed by noncanonical human DNA polymerasesChanges in Mitochondrial Toxicity in Peripheral Blood Mononuclear Cells During Four-Year Administration of Entecavir Monotherapy in Chinese Patients with Chronic Hepatitis BGenetic Evidence for Genotoxic Effect of Entecavir, an Anti-Hepatitis B Virus Nucleotide Analog.Adverse effects of oral antiviral therapy in chronic hepatitis B.Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901.First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practiceConsiderations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B.Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B.Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
P2860
Q27030828-EDC0846A-13A8-47C2-803E-B39C1A0F6D4AQ30885827-C32053B7-B209-4634-9470-D066A1ED78F3Q33754229-ED228744-5FAF-4A7A-AEC0-CB0D443A55DCQ34289964-DADAE943-776E-42FA-85E4-5E9B52933A61Q34431200-5647CC9F-BF25-4D2A-8670-5A8099CFC462Q34932672-14A35191-60D2-4704-890B-DEEBBFBB68F6Q35026611-9E04B7EB-4025-4B58-9A35-FCC8DCB06097Q35675387-4855E929-22A5-4D99-928C-4ABC5630F3BAQ35891653-560499DE-12A6-488F-A839-C0CA0FB1259FQ35901801-261398F6-0B1D-4D31-B710-D3A0449B0EB5Q37651892-8C3FC6E1-86A1-415E-B295-0040D8674119Q37964712-C41BDE4C-A3B7-470B-8AF0-0368FBB8AE9FQ37974690-76C47362-105C-420B-B3AC-7D0DAB63AF48Q38008777-BE464128-233B-4D5D-93F5-592719F5F1E4Q38067130-A092D02C-0323-4511-9209-03EF41590065Q43235917-49BEA312-CD96-4148-A1A4-170C1F2BC4D0Q47195767-BB5221C7-2344-42B4-BB99-760EB2E642D9Q52602046-AEEDE3F0-9590-4B29-A1A4-96CB94748010Q54377204-7AEA1C60-AF90-47A0-A970-7D1F9E934C7E
P2860
Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Entecavir for treatment of hep ...... A polymerase gamma inhibition.
@en
type
label
Entecavir for treatment of hep ...... A polymerase gamma inhibition.
@en
prefLabel
Entecavir for treatment of hep ...... A polymerase gamma inhibition.
@en
P2093
P2860
P356
P1476
Entecavir for treatment of hep ...... A polymerase gamma inhibition.
@en
P2093
Charles E Mazzucco
Daniel J Tenney
Richard J Colonno
Robert K Hamatake
P2860
P304
P356
10.1128/AAC.01122-07
P407
P577
2007-12-03T00:00:00Z